ZC3H13-mediated m6A stabilization of CCND1 promotes malignant progression and is associated with poor anti-PD-1 response in HNSCC

Abstract

Background: Resistance to immune checkpoint blockade substantially limits its clinical efficacy in head and neck squamous cell carcinoma(HNSCC). ZC3H13 is a component of the N6-methyladenosine writer complex, but its roles in HNSCC progression and response to anti-programmed cell death protein 1(anti-PD-1) therapy remain unclear.

Methods: The expression and clinical relevance of ZC3H13 were evaluated using clinical cohorts and publicly available transcriptomic datasets. Gain- and loss-of-function experiments were performed to determine the effects of ZC3H13 on the malignant phenotypes of HNSCC cells. An epithelial-specific ZC3H13 conditional knockout mouse model of 4-nitroquinoline-1-oxide-induced oral tumorigenesis was used to assess tumor development and responsiveness to anti-PD-1 therapy. N6-methyladenosine modification, RNA stability and functional rescue assays were conducted to investigate the underlying molecular mechanism.

Results: ZC3H13 was upregulated in HNSCC and was associated with poor prognosis and a limited response to anti-PD-1 treatment. ZC3H13 promoted the proliferation and invasion of HNSCC cells, whereas epithelial-specific ablation of ZC3H13 suppressed oral tumorigenesis and enhanced the therapeutic efficacy of anti-PD-1 treatment. Mechanistically, ZC3H13 regulated the N6-methyladenosine modification of cyclin D1(CCND1) mRNA and promoted its IGF2BP1-dependent stabilization, thereby contributing to malignant tumor phenotypes and alterations in immunosuppressvie features.

Conclusions: The ZC3H13/IGF2BP1/CCND1 regulatory axis contributes to HNSCC progression and resistance to anti-PD-1 therapy. These findings identify ZC3H13 as a potential therapeutic target for improving the efficacy of anti-PD-1 treatment in HNSCC.

Keywords

CCND1 / immunotherapy resistance / m6A modification / ZC3H13

References

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229-263.

[2] Diao P, Dai Y, Wang A, et al. Integrative multiomics analyses identify molecular subtypes of head and neck squamous cell carcinoma with distinct therapeutic vulnerabilities. Cancer Res. 2024; 84(18): 3101-3117.

[3] Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020; 6(1): 92.

[4] Kürten CHL, Kulkarni A, Cillo AR, et al. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nat Commun. 2021; 12(1): 7338.

[5] Tahara M, Lim DW, Keam B, et al. Management approaches for recurrent or metastatic head and neck squamous cell carcinoma after anti-PD-1/PD-L1 immunotherapy. Cancer Treat Rev. 2025; 136:102938.

[6] Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 2020; 37(4): 443-455.

[7] Bhatia A, Burtness B, Treating head and neck cancer in the age of immunotherapy: a 2023 update. Drugs. 2023; 83(3): 217-248.

[8] Chen Y, Wang D, Li Y, et al. Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer. Cancer Cell. 2024; 42(7): 1268-1285.e7.

[9] Liu S, Knochelmann HM, Lomeli SH, et al. Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. Cell Rep Med. 2021; 2(10):100411.

[10] Obradovic A, Graves D, Korrer M, et al. Immunostimulatory cancer-associated fibroblast subpopulations can predict immunotherapy response in head and neck cancer. Clin Cancer Res. 2022; 28(10): 2094-2109.

[11] Yan Y, Sun D, Hu J, et al. Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer. Nat Genet. 2025; 57(1): 126-139.

[12] Deng X, Qing Y, Horne D, Huang H, Chen J, The roles and implications of RNA m(6)A modification in cancer. Nat Rev Clin Oncol. 2023; 20(8): 507-526.

[13] Han X, Zhu Y, Ke J, et al. Progression of m(6)A in the tumor microenvironment: hypoxia, immune and metabolic reprogramming. Cell Death Discov. 2024; 10(1): 331.

[14] Chelmicki T, Roger E, Teissandier A, et al. m(6)A RNA methylation regulates the fate of endogenous retroviruses. Nature. 2021; 591(7849): 312-316.

[15] Su S, Li S, Deng T, et al. Cryo-EM structures of human m(6)A writer complexes. Cell Res. 2022; 32(11): 982-994.

[16] Xie X, Zhao Y, Liu J, et al. ZC3H13 mediates N6-methyladenosine modification of SNTB1 to promote epithelial-mesenchymal transition in gastric cancer. Cell Death Dis. 2025; 16(1): 596.

[17] Yan Q, Xu C, Gong L, et al. The role of ZC3H13 in promoting M2 macrophage infiltration via m6A methylation in esophageal squamous cell carcinoma tumor progression. Front Immunol. 2025; 16:1612041.

[18] Jiao X, Di Sante G, Casimiro MC, et al. A cyclin D1 intrinsically disordered domain accesses modified histone motifs to govern gene transcription. Oncogenesis. 2024; 13(1): 4.

[19] Zheng Y, Chen Y, Meng X, et al. FADD functions as an oncogene in Chr11q13.3-amplified head and neck squamous cell carcinoma. Cancer Res. 2025; 85(10): 1909-1927.

[20] Cai Z, Wang J, Li Y, et al. Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors. Sci China Life Sci. 2023; 66(1): 94-109.

[21] Shirole NH, Kesar D, Lee Y, et al. Requirement for cyclin D1 underlies cell-autonomous HIF2 dependence in kidney cancer. Cancer Discov. 2025; 15(7): 1484-1504.

[22] Huang H, Weng H, Sun W, et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018; 20(3): 285-295.

[23] Ying Y, Wu Y, Zhang F, et al. Co-transcriptional R-loops-mediated epigenetic regulation drives growth retardation and docetaxel chemosensitivity enhancement in advanced prostate cancer. Mol Cancer. 2024; 23(1): 79.

[24] Gerdemann U, Alvarez-Calderon F. Uncovering CD4+ T-cell exhaustion in B-ALL. Blood. 2022; 140(4): 294-296.

[25] Gilbert WV, Nachtergaele S. mRNA regulation by RNA modifications. Annu Rev Biochem. 2023; 92: 175-198.

[26] Han D, Xu MM. RNA modification in the immune system. Annu Rev Immunol. 2023; 41: 73-98.

[27] Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019; 394(10212): 1915-1928.

[28] Watermann C, Pasternack H, Idel C, et al. Recurrent HNSCC harbor an immunosuppressive tumor immune microenvironment suggesting successful tumor immune evasion. Clin Cancer Res. 2021; 27(2): 632-644.

[29] Quah HS, Cao EY, Suteja L, et al. Single cell analysis in head and neck cancer reveals potential immune evasion mechanisms during early metastasis. Nat Commun. 2023; 14(1): 1680.

[30] Wen J, Lv R, Ma H, et al. Zc3h13 regulates nuclear RNA m(6)A methylation and mouse embryonic stem cell self-renewal. Mol Cell. 2018; 69(6): 1028-1038.e6.

[31] Bawankar P, Lence T, Paolantoni C, et al. Hakai is required for stabilization of core components of the m(6)A mRNA methylation machinery. Nat Commun. 2021; 12(1): 3778.

[32] Qu Y, Gao N, Zhang S, et al. Role of N6-methyladenosine RNA modification in cancer. MedComm (2020). 2024; 5(9):e715.

[33] Monteagudo-García Ó, Nombela P, Román ÁC, et al. ZC3H13 loss drives cancer metastatic progression by disrupting m6A RNA methylation. Cancer Res. 2026; 86(3): 622-641.

[34] Zhu D, Zhou J, Zhao J, et al. ZC3H13 suppresses colorectal cancer proliferation and invasion via inactivating Ras-ERK signaling. J Cell Physiol. 2019; 234(6): 8899-8907.

[35] Davies A, Zoubeidi A, Beltran H, Selth LA. The transcriptional and epigenetic landscape of cancer cell lineage plasticity. Cancer Discov. 2023; 13(8): 1771-1788.

[36] Pang L, Zhou F, Liu Y, et al. Epigenetic regulation of tumor immunity. J Clin Invest. 2024; 134(12):e178540.

[37] Flamand MN, Tegowski M, Meyer KD. The proteins of mRNA modification: writers, readers, and erasers. Annu Rev Biochem. 2023; 92: 145-173.

[38] Sendinc E, Shi Y, RNA m6A methylation across the transcriptome. Mol Cell. 2023; 83(3): 428-441.

[39] Jiang X, Liu B, Nie Z, et al. The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther. 2021; 6(1): 74.

[40] Chen B, Huang R, Xia T, et al. The m6A reader IGF2BP3 preserves NOTCH3 mRNA stability to sustain Notch3 signaling and promote tumor metastasis in nasopharyngeal carcinoma. Oncogene. 2023; 42(48): 3564-3574.

[41] Wang J, Su W, Zhang T, et al. Aberrant Cyclin D1 splicing in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis. 2023; 14(4): 244.

[42] Chen Y, Huang Y, Gao X, et al. CCND1 amplification contributes to immunosuppression and is associated with a poor prognosis to immune checkpoint inhibitors in solid tumors. Front Immunol. 2020; 11: 1620.

[43] Ali LR, Garrido-Castro AC, Lenehan PJ, et al. PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer. J Exp Med. 2023; 220(4):e20220729.

[44] Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017; 548(7668): 471-475.

[45] Zhang S, Xu Q, Sun W, Zhou J, Zhou J. Immunomodulatory effects of CDK4/6 inhibitors. Biochim Biophys Acta Rev Cancer. 2023; 1878(4):188912.

[46] Wherry EJ. T cell exhaustion. Nat Immunol. 2011; 12(6): 492-499.

[47] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2): 228-247.

Rights & permissions

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.